Professional Documents
Culture Documents
Novel Microfluidic Technologies For Portable Diagnostics Systems
Novel Microfluidic Technologies For Portable Diagnostics Systems
UCIrvine
Outline
Background and motivation of microfluidics Microfluidics for TB serodiagnostics Microfluidics platforms for cell and biomolecular assays DARPA-Industry Micro/Nano Fluidics Fundamentals Focus (MF3) Center Summary
UCIrvine
UCIrvine
In 6 years
BioMEMS, BioChip, mTAS
electronics
optics
Days to hours
1 hour
Minutes to seconds
UCIrvine
Chip-Scale Integration for harnessing the power of electrons, photons and biomolecules
electronics photonics MEMS Microfluidics/LOC
Bot
1 mm
Data Com
Microfluidics
CMOS
VCSEL
UCIrvine
Lab on a Chip
Is it possible?
UCIrvine
Advantages of Microfluidics
Miniaturized channels and reservoirs High surface to volume ratio Low Reynolds number Increase speed of reaction Reduce cost of reagents Reduce power consumption Precise mixing/dosage and heating
Integration Reduce cost of manufacture Minimize dead space, void volume Minimize sample carryover Multiplex capability: increased number of parameters monitored per assay
20 m
Hong & Quake, Nat. Biotech 2003
UCIrvine
Perhaps the need for >15 billion molecular tests per year
Courtesy: Peter Gascoyne - UT MDACC
UCIrvine
1900s-2000 Centralized laboratories to which samples are brought and processed by skilled operators
UCIrvine
TB Conference, VA Beach, September 23, 2008
1950s 1970s Centralized computers to which the data is brought and processed by skilled operators
UCIrvine
Microprocessors
UCIrvine
Lab testing/Diagnostics
Microfluidic Processors
UCIrvine
Centrifugation Thermocyclers
Amplification
Hybridization
Separation Hybridization
Conventional DNA Microarray
Readers
Detection
UCIrvine
Answer
Projects
Acoustic agitator active mixing Electrical detection of protein binding Molecular spotting in microchannels Colorimetric imaging by scanner Other projects
Droplet DNA analysis Droplet lipoplex Cell sorting
UCIrvine
Disease Stage ID
0 Healthy Control 1 Primary Infection 2 Disseminated Disease 3 Chronic Disease
The Protein Microarray Laboratory (PML) at UC Irvine has developed a high-throughput genome cloning, expression and printing platform to generate protein microarrays on a genome-wide scale for vaccine and serodiagnostic antigen discovery. High density whole microorganism protein microarrays are printed on nitrocellulose coated glass slides and probed with human infected sera to identify serodominant antigens potentially useful for diagnostic tests, and vaccine discovery.
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43
1.0
4.0
8.0
Lyme Disease
TB Conference, VA Beach, September 23, 2008
UCIrvine
Traditional Microarray
Protein Microarrays 100-200 micron antigen spots or biomarkers on a finger-nail sized nitrocellulose pad 250-4000 biomarkers per pad Approximately 24hrs for complete assay to be run Uses fluorescent scanner for antigen-antibody detection
UCIrvine
UCIrvine
Platform 1: Flow-induced Electrical Admittance Biosensor (FEAB) A microfluidic electrical sensing platform that is capable of detecting antigen/antibody binding in real time. The development of this platform will allow for faster detection of certain illnesses and diseases within a patients sample compared to standard techniques such as ELISA.
UCIrvine
UCIrvine
Time 0 sec
Time 1 sec
Time 3 sec
Time 6 sec
Thiolene device: 4x4 array of 400 micron cavities at 400 micron depth within an channel approximately 1000microns deep
UCIrvine
Colorimetric Enhancement
Colorimetric Results
UCIrvine
Lab in a Droplet!
Advantages of Droplets Rapid mixing Homogeneous reactions Precise control of volumes Precise control of concentrations Mimic cellular reactions
Analog
Digital microfluidics
TB Conference, VA Beach, September 23, 2008
UCIrvine
vs
UCIrvine
VS
Microarray
Droplet array
Droplet arrays provides a versatile screening platform for biochemistry and molecular biology.
UCIrvine
TB Conference, VA Beach, September 23, 2008
UCIrvine
To product reservoir
UCIrvine
UCIrvine
UCIrvine
UCIrvine
Flanagan et al., Stem Cells 2008 Abe Lee, Lisen Wang, Jente Lu UCIrvine
TB Conference, VA Beach, September 23, 2008
efieldy 1.00E+005 --
-1.00E+005 --
Integration of in vitro Diagnostics with in vivo Therapy Changing the current healthcare paradigm
Biomedicine Pull:
-Disease diagnostics -Disease treatment -Disease monitoring -Disease prevention Detection
Detection
Sensing Signaling
Diagnosis
Effector Action Data Analysis
Treatment
Technology Push:
- Lab on a chip - Drug discovery - Drug delivery - Implants - Surgical tools - Biosensors - Imaging Treatment
Judgement
Diagnosis
UCIrvine
UCIrvine
UCIrvine
UCIrvine
Collaborators
Dr. Phil Felgner, molecular biology/UCI Prof. Paul Dayton BME/U. of North Carolina Prof. Sadik Esener, EECS/Nanotumor/UCSD Prof. Hugh Fan ME/University of Florida Dr. Lisa Flanagan, pathology/UCI Prof. Jamie Jester, opthalmology/UCI Dr. Peter Lee, BME/Singapore DSO/NUS) Prof. Ed Monuki, pathology/UCI Prof. Ken Shea, chemistry/UCI Prof. Jeff Wang ME/Johns Hopkins Prof. Dan Nicolau ChemE/U of Liverpool
UCIrvine
UCIrvine